Abstract: The use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at risk of death, in a method for assessing the severity of a disease caused by a coronavirus such as COVID-19, and in a method for monitoring a subject suffering from a disease caused by a coronavirus such as COVID-19.

Abstract: Systems and methods are disclosed for visualizing reentrant circuits in the heart via pseudo-activation maps. Techniques disclosed comprise receiving sets of ECG data and respective pacing sites. Each of the sets is generated by pacing heart tissue at a respective site of the pacing sites. Techniques disclosed further comprise computing correlation gradients representative of morphological changes across sets, of the sets of the ECG data, of respective neighboring sites of the pacing sites. Based on the computed correlation gradients, a core zone associated with a reentrant circuit is identified. Then, relative to the identified core zone, one or more pseudo-activation maps are generated.

Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.